Bogazzi Fausto, Bartalena Luigi, Tomisti Luca, Rossi Giuseppe, Tanda Maria Laura, Dell'Unto Enrica, Aghini-Lombardi Fabrizio, Martino Enio
Department of Endocrinology, University of Pisa, Ospedale Cisanello, Via Paradisa, 2, 56124 Pisa, Italy.
J Clin Endocrinol Metab. 2007 Feb;92(2):556-62. doi: 10.1210/jc.2006-2059. Epub 2006 Dec 5.
Amiodarone-induced thyrotoxicosis (AIT) resulting from destructive thyroiditis (type 2) is commonly treated with glucocorticoids, but time needed to restore euthyroidism may be unacceptable for patients with underlying cardiac disorders.
The objective of this prospective study was to identify factors affecting the response to glucocorticoids in a large cohort of patients with type 2 AIT followed prospectively.
This study was conducted at university centers.
Sixty-six untreated patients with type 2 AIT were enrolled in the study.
All patients were treated with prednisone (initial dose, 0.5 mg/kg.d) as long as needed to restore euthyroidism, defined as cure of AIT.
The main outcome measure was cure time.
The median cure time was 30 d (95% confidence interval, 23-37 d). Serum free T4 concentration (picograms per milliliter) and thyroid volume (milliliters per square meter) (and, to a lesser extent, serum free T3 concentration) at diagnosis were the main determinants of response to glucocorticoids, with a cure hazard ratio of 0.97 (95% confidence interval, 0.95-0.99; P = 0.005) and 0.84 (95% confidence interval, 0.77-0.91; P = 0.000) for unit of increment, respectively. AIT was cured in all patients with a complete follow-up; euthyroidism was reached in 30 d or less in 60% of patients but in more than 90 d in 16%. A prompt control of thyrotoxicosis (<or=30 d of treatment) was more frequent (77%) in patients with serum basal free T4 concentration no greater than 50 pg/ml and thyroid volume (normalized for body surface area) no greater than 12 ml/m2. The cure probability and the mean cure time in an individual patient can be obtained using a formula generated by multiple regression models.
Baseline serum thyroid hormone concentrations and thyroid volume help identify patients with type 2 AIT at risk of a delayed response to glucocorticoids.
由破坏性甲状腺炎(2型)导致的胺碘酮所致甲状腺毒症(AIT)通常采用糖皮质激素治疗,但对于患有基础心脏疾病的患者而言,恢复甲状腺功能正常所需的时间可能难以接受。
这项前瞻性研究的目的是在一大群前瞻性随访的2型AIT患者中确定影响对糖皮质激素反应的因素。
本研究在大学中心进行。
66例未经治疗的2型AIT患者纳入本研究。
所有患者均接受泼尼松治疗(初始剂量,0.5mg/kg·d),持续至恢复甲状腺功能正常(定义为AIT治愈)所需的时间。
主要结局指标为治愈时间。
中位治愈时间为30天(95%置信区间,23 - 37天)。诊断时的血清游离T4浓度(皮克/毫升)和甲状腺体积(毫升/平方米)(以及在较小程度上血清游离T3浓度)是对糖皮质激素反应的主要决定因素,每增加一个单位的治愈风险比分别为0.97(95%置信区间,0.95 - 0.99;P = 0.005)和0.84(95%置信区间,0.77 - 0.91;P = 0.000)。所有完成随访的患者AIT均治愈;60%的患者在30天或更短时间内达到甲状腺功能正常,但16%的患者超过90天。血清基础游离T4浓度不高于50 pg/ml且甲状腺体积(根据体表面积标准化)不高于12 ml/m2的患者中,甲状腺毒症的快速控制(治疗≤30天)更为常见(77%)。个体患者的治愈概率和平均治愈时间可使用多元回归模型生成的公式获得。
基线血清甲状腺激素浓度和甲状腺体积有助于识别2型AIT患者中对糖皮质激素反应延迟风险的患者。